Paradigm Biopharmaceuticals (PAR.AX) Earnings Analysis
Paradigm Biopharmaceuticals (PAR.AX) next reports earnings on 2026-08-21. Trailing P/E -1.96.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does PAR.AX next report earnings?
| Next earnings date | 2026-08-21 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | 0.00B |
PAR.AX earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-02-26 | -0.0562 AUD | n/a | n/a | n/a |
| 2025-04-28 | -0.01673 AUD | n/a | n/a | n/a |
| 2024-10-31 | -0.03381 AUD | n/a | n/a | n/a |
PAR.AX valuation and analyst view
| Trailing P/E | -1.96 |
|---|---|
| Trailing EPS | -0.08721 AUD |
| Price / book | 12.07 |
| Dividend yield | 0.00% |
| Market cap | 0.08B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Paradigm Biopharmaceuticals (PAR.AX)'s next earnings date?
Paradigm Biopharmaceuticals is next scheduled to report on 2026-08-21 and revenue estimate of 0.00B.
Did PAR.AX beat earnings last quarter?
Consensus estimate data was not available for PAR.AX's 2026-02-26 report.
What is PAR.AX's current P/E ratio and EPS?
PAR.AX trades at a trailing P/E of -1.96 on trailing EPS of -0.08721259824839582 AUD.
What do analysts rate PAR.AX?
PAR.AX has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.